Lidocaine

An amide local anesthetic used as skin patches and creams for nerve and minor pain and as injections for local or nerve-block numbing.

psilodex.org/m/lidocaine · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~1.8 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Lidocaine”, v2026.10.05. psilodex.org/m/lidocaine

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Rx (5% patch, injection) and OTC (lower-strength creams and patches)

FDA-approved for

Pain after shingles (post-herpetic neuralgia) (5% patch)
Local or regional anesthesia by infiltration or peripheral nerve block (injection)

Sources [1][2]

Other safety

Labels report methemoglobinemia with local anesthetics, and a used 5% patch still holds a large amount of lidocaine that could harm a child or pet.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; no linking mechanism is described. Also, skin forms are barely absorbed; high blood levels from injection can cause confusion or seizures.

Detail Lidocaine has no known interaction with psilocybin. Applied to the skin, very little reaches the blood. With the 5% patch, about 3% of the dose is absorbed, giving blood levels about one tenth of those used to treat heart rhythm problems. Also, when injected for local or nerve-block anesthesia, high blood levels can cause dizziness, confusion, drowsiness or seizures. This happens mostly with overdose or accidental injection into a vessel. Sources [1][2]

Human data with psilocybin: No psilocybin data; based on its label
Half-life: ~1.8 h (81–149 min after IV dosing) (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Lidocaine Patch 5% (Par Health) · FDA label (DailyMed) — "only 3 ± 2% of the dose applied is expected to be absorbed" "Mean peak blood concentration of lidocaine is about 0.13 mcg/mL (about 1/10 of the therapeutic concentration" | "Systemic adverse reactions following appropriate use of LIDOCAINE PATCH 5% are unlikely, due to the small dose absorbed" | "Cases of methemoglobinemia have been reported in association with local anesthetic use." | "The half-life of lidocaine elimination from the plasma following IV administration is 81 to 149 minutes"
Lidocaine Hydrochloride Injection, USP (infiltration and nerve block) · FDA label (DailyMed) — Adverse Reactions, Central Nervous System "CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness" "convulsions"
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →